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ABSTRACT
Esophageal cancer is the sixth most common cause of cancer-related deaths 
worldwide. Novel therapeutic intervention is urgently needed for this deadly disease. 
The functional role of PI3K/AKT pathway in esophageal cancer is little known. 
In this study, our results from 49 pairs of human esophageal tumor and normal 
specimens demonstrated that AKT was constitutively active in the majority (75.5%) 
of esophageal tumors compared with corresponding normal tissues. Inhibition of the 
PI3K/AKT pathway with specific inhibitors, wortmannin and LY294002, significantly 
reduced Bcl-xL expression, induced caspase-3-dependent apoptosis, and repressed 
cell proliferation and tumor growth in vitro and in vivo without obvious toxic effects. 
Moreover, significantly higher expression level of p-AKT was observed in fluorouracil 
(5-FU)-resistant esophageal cancer cells. Inactivation of PI3K/AKT pathway markedly 
increased the sensitivity and even reversed acquired resistance of esophageal cancer 
cells to chemotherapeutic drugs in vitro. More importantly, the resistance of tumor 
xenografts derived from esophageal cancer cells with acquired 5-FU resistance to 
chemotherapeutic drugs was significantly abrogated by wortmannin treatment in 
animals. In summary, our data support PI3K/AKT as a valid therapeutic target and 
strongly suggest that PI3K/AKT inhibitors used in conjunction with conventional 
chemotherapy may be a potentially useful therapeutic strategy in treating esophageal 
cancer patients. 
INTRODUCTION
Esophageal cancer is the 8th most common cancer 
in the world. Although the incidence rate of esophageal 
cancer pales in comparison with that of cancers of breast, 
prostate, colon, and lung, it has a very high lethality rate, 
with more than 400,000 deaths (i.e. around 90% of the 
incidence of the disease) reported in 2012 [1, 2]. The 
5-year survival rate of patients with esophageal cancer 
rarely exceeds 40% [3]. Local recurrence after initial 
treatment is still the major cause of treatment failure in the 
patients [4, 5]. Thus, a detailed study of esophageal cancer 
including identification and better understanding of the 
key signaling pathways responsible for development and 
progression of this disease is urgently needed to develop 
new treatment strategies.
Genetic abnormalities of the phosphatidylinositil-3- 
kinase (PI3K)/AKT pathway are common in human 
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cancer, and there is increasing evidence of PI3K/AKT 
being involved in the development of many types of 
cancers [6, 7], thus making PI3K/AKT and its downstream 
pathways promising targets for therapeutic intervention [8, 
9]. However, the role of PI3K/AKT signaling pathway in 
esophageal tumorigenesis is not fully understood and the 
feasibility of targeting PI3K/AKT as a potential treatment 
for esophageal cancer has not been elucidated. Recent 
immunohistochemical studies including ours showed that 
PI3K/AKT is constitutively activated in human esophageal 
tumor tissues [10], but studies that evaluate PI3K/AKT 
signaling based on matched tumor and normal tissues are 
limited. More importantly, there is currently very little in 
vitro or in vivo experimental data on the effects of PI3K/
AKT inhibition on esophageal cancer.
Intrinsic and acquired resistance to 
chemotherapeutic drugs in human cancer may lead to poor 
treatment response or cancer recurrence. Fluorouracil (5-
FU) is a key chemotherapy drug for esophageal cancer. 
We recently established 5-FU-resistant (FR) cell lines 
by treating esophageal cancer cells with increasing 
concentration of 5-FU for over one year [11], and here 
we observed significantly increased expression of 
phosphorylated-AKT (p-AKT), the activated form of 
AKT, in the FR cells. In the present study, we aim to 
demonstrate, the significance of PI3K/AKT activation in 
esophageal cancer by examining the p-AKT expression 
in paired clinical tumor and normal specimens, and to 
determine the effects of specific inhibitors of PI3K/AKT 
on caspase-3-dependent cancer cell apoptosis, esophageal 
tumor growth and chemoresistance by in vitro experiments 
and in vivo tumorigenesis model.
RESULTS
PI3K/AKT pathway is constitutively activated in 
esophageal tumors compared with paired normal 
tissues
To study whether the PI3K/AKT signaling pathway 
is clinically relevant in esophageal cancer, the expression 
levels of p-AKT and total AKT were determined in 49 
pairs of human esophageal tumor and adjacent normal 
tissues (Figure 1A). Compared with the corresponding 
normal tissues, a higher p-AKT/total AKT ratio was 
observed in the majority of primary esophageal tumors 
studied (37 of 49; 75.5%) (Figure 1B). As seen in Figure 
1C, the mean p-AKT/total AKT ratio in the tumor tissues 
was about 2-fold higher than that in the paired normal 
tissues (0.40 ± 0.32 versus 0.21 ± 0.17; P < 0.001). 
These data highlighted the clinical relevance of the PI3K/
AKT pathway and its potential as therapeutic target in 
esophageal cancer.
Figure 1: Constitutive activation of PI3K/AKT signaling pathway in esophageal cancer. (A) Expression levels of p-AKT 
and total AKT were determined in 49 pairs of esophageal tumor and matched normal tissues by Western blot, and results of 6 representative 
esophageal tumor tissues (T) and their matched normal tissues (N) were shown. Actin was included as loading control. (B) p-AKT/total 
AKT ratio in 49 tumor tissues relative to matched normal esophageal tissues. Higher ratio of p-AKT to total AKT was found in 75.5% (37 
of 49) of human primary esophageal cancer, compared with their corresponding normal tissues. (C) Comparison of p-AKT/total AKT ratios 
between tumor tissues and normal tissues. The boxes contain the values between 25th and 75th percentiles of the 49 cases, and the whiskers 
extend to the highest and lowest values. The lines across the boxes indicate the median values, and the white diamonds inside the boxes 
represent the mean values. 
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PI3K/AKT inhibition decreases Bcl-xL expression 
and induces apoptosis in esophageal cancer cells
Two specific inhibitors, wortmannin and LY294002, 
were used in this study to block the PI3K/AKT 
signaling pathway. As shown in Figure 2A, treatment 
with wortmannin resulted in a dose-dependent reduced 
phosphorylation of AKT (p-AKT) and its downstream 
target GSK3β (p-GSK3β), but not total AKT or GSK3β, 
in four esophageal cancer cell lines, KYSE150, HKESC-1, 
KYSE270, and T.Tn. In addition, decreased Bcl-xL and 
increased cleaved caspase-3 expressions were detected 
upon treatment, although the expression level of Bax and 
caspase-3 remained stable (Figure 2A). These experiments 
were repeated with LY294002 in the four cell lines and 
similar results were obtained (Figure 2B). We also found 
that wortmannin and LY294002 significantly increased the 
Figure 2: Effects of wortmannin and LY294002 on PI3K/AKT pathway and expressions of apoptosis-associated 
proteins. Four esophageal cancer cell lines were treated with different concentrations of wortmannin (A) or LY294002 (B) respectively 
for 48 h, and cell lysates were collected for Western blot analysis of p-AKT, AKT, p-GSK3β, GSK3β, Bcl-xL, Bax, caspase-3, and cleaved 
caspase-3. (C) Comparison of sub-G1 population percentage by flow cytometry in the esophageal cancer cells treated with wortmannin (40 
µM), LY294002 (40 µM), Z-DEVD-FMK (50 µM) alone, or a combination of Z-DEVD-FMK and wortmannin or LY294002. Bars, SD; 
*** P < 0.001 compared with DMSO-treated cells.
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percentage of sub-G1 esophageal cancer cell population, 
whereas addition of Z-DEVD-FMK, a caspase-3 inhibitor, 
markedly abrogated these effects (Figure 2C). These data 
indicated that wortmannin and LY294002 exerted dose-
dependent inhibitory effects on the PI3K/AKT pathway 
and pro-apoptotic proteins, therefore inducing caspase-3-
dependent apoptosis in esophageal cancer cells. 
Wortmannin and LY294002 reduce proliferation 
and colony-formation ability of esophageal cancer 
cells
The esophageal cancer cell lines KYSE150, 
HKESC-1, KYSE270, and T.Tn were exposed to 
different concentrations of wortmannin or LY294002, 
and the results from MTT and colony-formation assays 
showed that blockade of PI3K/AKT pathway inhibited 
proliferation (Figure 3) and colony-formation ability 
(Figure 4) of esophageal cancer cells, suggesting that 
specific inhibitors of PI3K may have antitumor effects.
Wortmannin suppresses growth of human 
esophageal cancer xenografts in nude mice
Nude mice bearing human esophageal tumor 
xenografts were used to test the therapeutic potential of 
wortmannin in vivo. As shown in Figure 5A, treatment 
with wortmannin for 19 days caused a significant dose-
Figure 3: Effects of PI3K/AKT inhibitors on esophageal cancer cell proliferation. MTT assay was used to determine the 
effects of different concentrations of wortmannin (A) and LY294002 (B) on viability of esophageal cancer cells lines KYSE150, HKESC-1, 
KYSE270, and T.Tn. Bars, SD; * P < 0.05; **, P < 0.01; ***, P < 0.001 compared with DMSO-treated cells.
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dependent suppression of tumor volume, with decreases 
of 59.2% and 77.3% for KYSE150 and KYSE270 
tumors, respectively, in the groups receiving 0.6 mg/kg 
wortmannin treatment. Western blot analysis of tumor 
xenografts showed that wortmannin treatment resulted 
in inactivation of PI3K/AKT pathway and induction 
of apoptosis, as indicated by the decreased expression 
levels of p-AKT and p-GSK3β, as well as increased 
cleaved caspase-3. Notably, wortmannin treatment had 
a better response in suppressing growth of KYSE270 
tumor xenografts, which expressed higher level of p-AKT 
(Figure 5B). There was no significant difference between 
the treated and control groups in terms of body weight 
(Figure 5C) and morphology of lung, liver, and kidneys 
(Figure 5D), suggesting no obvious adverse effects on 
animals.
Figure 4: Effects of PI3K/AKT inhibitors on colony-formation ability of esophageal cancer cells. Colony-formation assay 
showed that exposure of the four esophageal cancer cell lines to wortmannin (A) and LY294002 (B) decreased colony-formation ability in 
a dose-dependent manner. Bars, SD; * P < 0.05; **, P < 0.01; ***, P < 0.001 compared with DMSO-treated cells.
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PI3K/AKT inhibition enhances the sensitivity 
of esophageal cancer cells to chemotherapeutic 
drugs in vitro and in vivo
The effects of PI3K/AKT inhibitors on 
chemoresistance were studied. The MTT (Figure 6A) 
and colony-formation assays (Figure 6B) data showed 
that PI3K/AKT inhibition significantly increased the 
sensitivity of esophageal cancer cell lines to 5-FU and 
cisplatin (DDP). The effect of wortmannin in repressing 
chemoresistance was also investigated in vivo. Nude 
mice bearing KYSE270 tumor xenografts were treated 
with 5-FU and cisplatin, with or without wortmannin. 
The results demonstrated that wortmannin treatment 
significantly enhanced the sensitivity of the esophageal 
tumor xenografts to chemotherapeutic drugs in animals 
(Figure 6C).
Figure 5: Effects of wortmannin on suppressing growth of human esophageal tumor xenografts in nude mice. (A) Human 
esophageal cancer cells KYSE150 (left panel) and KYSE270 (right panel) were injected subcutaneously into the flanks of nude mice (n = 6 
per group). Treatment of the mice with 0.6 mg/kg wortmannin twice a week significantly delayed the growth of the tumor xenografts. Note 
that the treatment had a better response in KSYE270-derived xenografts. (B) Western blot analysis indicated reduced expression levels of 
p-AKT, p-GSK3β, and increased cleaved caspase-3 in the tumors of wortmannin-treated mice, compared with the DMSO-treated group. 
(C, D) Comparison of body weight (C) and histological examination of lung, liver and kidney specimens (D) between wortmannin-treated 
and vehicle-treated animals showed no toxic effects. Bars, SD; *** P < 0.001 compared with DMSO-treated mice.
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Figure 6: Effects of PI3K/AKT inhibitors on sensitivity of esophageal cancer cells to conventional chemotherapeutic 
drug in vitro and in vivo. (A) Esophageal cancer cells were treated with wortmannin (5 µM), LY294002 (5 µM), 5-FU (2.5 µM), DDP 
(10 µM), wortmannin plus 5-FU, wortmannin plus DDP, LY294002 plus 5-FU, or LY294002 plus DDP, and cell viability and colony-
formation ability measured by MTT (A) and colony-formation assays (B). (C) Nude mice xenografted with human esophageal cancer cells 
KYSE270 were treated with wortmannin (0.3 mg/kg), 5-FU (20 mg/kg), DDP (2 mg/kg), a combination of wortmannin and 5-FU, or a 
combination of wortmannin and DDP twice weekly (n = 6 per group). Bars, SD; *** P < 0.001 compared with 5-FU- or DDP-treated cells 
or mice.
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PI3K/AKT inhibition reverts acquired 
chemoresistance of 5-FU-resistant (FR) 
esophageal cancer cells to chemotherapeutic 
drugs in vitro and in vivo
We then proceeded to investigate the role of 
PI3K/AKT pathway in acquired chemoresistance. 
Interestingly, increased activation of PI3K/AKT pathway, 
indicated by higher p-AKT expression, was observed 
in the FR cells compared with corresponding parental 
cells (Figure 7A), suggesting the significance of PI3K/
AKT in acquired chemoresistance in esophageal cancer 
cells. This prompted us to explore whether PI3K/AKT 
inhibitors can inhibit the proliferation of FR esophageal 
cancer cells in 5-FU. The results showed that although 
5-FU, wortmannin, or LY294002 alone at the dosages 
used had no or only slight effects on the proliferation of 
KYSE150FR and KYSE410FR cells, combining 5-FU 
with wortmannin or LY294002 significantly reverted the 
Figure 7: Effects of PI3K/AKT inhibition on reversing resistance of FR cells to 5-FU. (A) Western blot analysis of expression 
levels of p-AKT and AKT in FR and corresponding parental cells. The bands were quantified using ImageJ. (B) Comparison of the viability 
of FR esophageal cancer cells treated with 5-FU (40 µM for KYSE150FR and 10 µM for KYSE410FR), wortmannin (5 µM), LY294002 
(5 µM) alone, or a combination of 5-FU and wortmannin or LY294002. (C-D) Parental KYSE150 and KYSE410 cells were treated with 
5-FU, whereas the respective FR cells were treated with 5-FU, wortmannin, LY294002 alone, or the combination of 5-FU and wortmannin 
or LY294002 for 48 h. The drugs were used at the same concentrations as in (B). The cells were collected for cell cycle analysis of sub-G1 
population percentage using flow cytometry (C), and for Western blot analysis of caspase-3 and cleaved caspase-3 (D), respectively. (E) 
Nude mice bearing KYSE410FR-derived tumor xenografts were treated with wortmannin (0.3 mg/kg), 5-FU (20 mg/kg), or a combination 
of wortmannin and 5-FU twice weekly for three weeks (n = 6 per group). Bars, SD; * P < 0.05; **, P < 0.01; ***, P < 0.001.
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resistance and lowered the proliferation rate (Figure 7B). 
Furthermore, the FR cell lines which were resistant to 
5-FU-induced apoptosis were rendered apoptotic by the 
addition of wortmannin or LY294002, as evidenced by 
the increase in sub-G1 population and cleaved caspase-3 
expression (Figure 7C-D). More importantly, our in vivo 
experiments showed that the resistance of KYSE410FR 
tumor xenografts to 5-FU treatment in nude mice was 
markedly abrogated by wortmannin treatment (Figure 
7E). Taken together, the above findings indicated that 
blockade of PI3K/AKT can reverse acquired resistance of 
FR esophageal cancer cells to chemotherapy drugs.
DISCUSSION
PI3K is a lipid kinase that generates second 
messenger lipid phosphatidylinositol (3-5)-triphosphate 
(PIP3), which recruits and activates a number of proteins 
including AKT. AKT encodes a serine/threonine kinase, 
and is activated through phosphorylation, which mediates 
the activation of target genes, therefore regulating cell 
proliferation, survival, angiogenesis, invasion and 
metastasis. Constitutively activated PI3K/AKT pathway 
is a common event in many types of cancer, and is 
associated with poor prognosis and reduced survival [6, 
7, 12]. In esophageal cancer, the association of genetic 
variants of AKT with chemoradiotherapy response and 
survival has been reported [13]. Our previous studies 
demonstrated constitutive activation of the PI3K/AKT 
pathway in esophageal tumor tissues and its regulation by 
Id1 (inhibitor of differentiation or DNA binding) [10, 14]. 
In this study, Western blot analysis of clinical esophageal 
tumor specimens demonstrated markedly higher p-AKT 
expression in tumor tissues compared with paired normal 
tissues.
The significance of PI3K/AKT and its potential 
as a therapeutic target for cancer treatment have been 
investigated in several types of human cancer in 
preclinical studies, including renal cancer [15], lung 
cancer [16], breast cancer [17], glioblastoma [18], and 
neuroblastoma [19]. More importantly, the data from 
phase I clinical trial suggested that treatment of the 
cancer patients with PI3K inhibitors was associated with 
prolonged stable disease, and phase II trials are in progress 
[20, 21]. Although overexpression of PTEN (phosphatase 
and tensin homolog), which acts as a lipid phosphatase 
to dephosphorylates PIP3 and therefore negatively 
regulates PI3K/AKT pathway, was found to suppress 
esophageal cancer cell growth [22], experimental data 
on direct targeting of PI3K/AKT in the preclinical setting 
are limited. Our in vitro and in vivo results showed that 
specific inhibitors of PI3K/AKT inhibited proliferation 
and promoted apoptosis of esophageal cancer cells in a 
dose-dependent manner (Figures 2-5), thus indicating the 
therapeutic potential of targeting PI3K/AKT in esophageal 
cancer treatment. 
Chemotherapy is now widely used in clinical 
cancer treatment but development of chemoresistance 
can compromise treatment or even result in recurrence 
of the disease. The contribution of chemoresistance to 
low survival rate of human cancer patients has therefore 
prompted studies that explore the underlying mechanisms. 
Here, we found increased constitutive activity of the PI3K/
AKT signaling pathway in esophageal cancer cells with 
acquired resistance to 5-FU. Several in vitro studies have 
shown that inhibition of PI3K/AKT pathway can sensitize 
a variety of other types of cancer cells to chemotherapeutic 
drugs [23, 24], but the effects of specific inhibitors of 
PI3K/AKT on esophageal cancer chemoresistance have 
not been reported. Our current findings showed for the 
first time that wortmannin and LY294002 significantly 
enhanced the sensitivity of parental esophageal cancer 
cells and chemoresistant sublines to chemotherapeutic 
drugs not only in vitro, but also in xenografted animal 
models (Figures 6-7), which strongly suggest that 
combining PI3K/AKT inhibitors and conventional 
chemotherapeutic drugs may be a potentially useful 
therapeutic strategy in treating esophageal cancer patients, 
particularly as upfront therapy before tumors have a 
chance to develop chemoresistance. This notion is further 
corroborated by Yoshioka et al.’s multivariate analysis 
of paired esophageal tumor samples obtained before and 
after chemotherapy, which shows that p-AKT expression 
is the only independent predictor of poor prognosis in 
esophageal cancer patients with chemotherapy [25]. 
Taken together, we have demonstrated the 
significance of PI3K/AKT pathway in malignant 
progression of esophageal cancer, and have provided 
the first evidence that PI3K/AKT inhibitors can increase 
the sensitivity and even reverse acquired resistance of 
esophageal cancer cells to chemotherapeutic drugs. 
Genetic mutations in the PI3K/AKT pathway are common 
in human cancer [26]. A recent study showed that patients 
with gynecologic and breast cancer that have PIK3CA 
mutations are more responsive to treatment with PI3K/
AKT/mTOR inhibitors than patients without mutations 
[21]. The effects of PI3K/AKT inhibitors on esophageal 
cancer with genetic variations in the PI3K/AKT pathway 
warrant further investigation.
MATERIALS AND METHODS
Cell culture and drugs
Human esophageal cancer cell lines KYSE150, 
KYSE270 [27], HKESC-1 [28], T.Tn [29], and the 5-FU-
resistant cell lines (KYSE150FR, KYSE410FR) we 
established previously [11] were maintained in RPMI 
1640 (Sigma, St. Louis, MO) supplemented with 10% 
fetal bovine serum (Invitrogen, Gaithersburg, MD) at 37 
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ºC in 5% CO2. Wortmannin, LY294002, 5-FU, cisplatin 
purchased from Calbiochem (Darmstadt, Germany), and 
Z-DEVD-FMK (Cayman Chemical, Ann Arbor, MI) were 
dissolved in DMSO. 
Esophageal cancer patient tissue specimens 
Fresh human esophageal tumor and the 
corresponding adjacent non-neoplastic esophageal tissues 
were collected with informed consent and Institutional 
Review Board approval from 49 patients undergoing 
surgical resection of primary esophageal tumor at Queen 
Mary Hospital in Hong Kong from 2011 to 2014, and at 
the First Affiliated Hospital, Zhengzhou University in 
Zhengzhou from 2008 to 2010. All specimens were snap-
frozen immediately in liquid nitrogen and stored at -80ºC.
Western blot
Preparation of cell and tumor lysates, and details 
of immunoblotting were described previously [14]. 
The primary antibodies used included phospho-AKT 
(Ser473), AKT, phospho-GSK3 (Ser9), GSK3β, Bcl-xL, 
Bax, caspase-3 and cleaved caspase-3 obtained from Cell 
Signaling Technology (Beverly, MA), and actin from 
Santa Cruz Biotechnology (Santa Cruz, CA). 
3-(4,5-Dimethyl thiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT) assay
Cell viability was measured using MTT assay [30]. 
The absorbance was measured at a wavelength of 570 
nm on a Labsystems Multiskan microplate reader (Merck 
Eurolab, Dietikon, Switzerland).
Colony-formation assay
Colony-formation assay was carried out as described 
previously [30]. Briefly, about 500 cells were seeded per 
well in 6-well-plates 24 h before the addition of drugs. 
After 14 days, the cells were fixed in 75% ethanol and 
stained with 0.2% crystal violet. The numbers of colonies 
were counted using QuantityOne software (Bio-Rad, 
Hercules, CA).
Flow cytometric cell cycle analysis 
Esophageal cancer cells were harvested and washed 
in PBS, then fixed in 70% ethanol. Cells were washed and 
incubated in propidium iodide (PI) staining buffer (PBS 
containing 40 µg/ml PI and 40 µg/ml RNase) at 37 ºC for 
30 min. The sub-G1 percentage of samples was determined 
on a BD FACSCanto II Analyzer (BD Biosciences, San 
Jose, CA) and data analyzed using FlowJo software (Tree 
Star Inc., Ashland, OR).
Tumorigenicity in nude mice
Female BALB/c nude mice aged 6-8 weeks were 
maintained under standard conditions and cared for 
according to the institutional guidelines for animal care. 
The esophageal cancer cells suspended in a 1:1 mixture of 
PBS/Matrigel were subcutaneously injected into the flank 
of mice. The mice were randomized into treatment and 
control groups when the tumors reached ~5 mm diameter. 
The treatment groups received wortmannin (0.3 mg/kg 
or 0.6 mg/kg), 5-FU (20 mg/kg) or cisplatin (2 mg/kg) 
through intraperitoneal injection twice weekly, whereas 
the control groups received the vehicle only. Additional 
treatment groups were given wortmannin (0.3 mg/kg) 
combined with 5-FU (20 mg/kg) or cisplatin (2 mg/kg). 
The body weight of mice was monitored weekly during 
the experiments to evaluate overall health. Tumor size was 
measured with calipers every three days and tumor volume 
was calculated using the equation V= (length x width2) /2. 
Tumors, together with pieces of liver, lung, and kidney, 
were collected at the end of experiments for further 
analyses. All the animal experiments were approved by 
the Committee on the Use of Live Animals in Teaching 
and Research of the University of Hong Kong.
Statistical analysis
The data were expressed as the mean ± SD and 
compared using ANOVA. P values < 0.05 were deemed 
significant. All in vitro experiments were repeated at least 
three times.
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